Publication:

A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis

Loading...
Thumbnail Image

Date

2016

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Nature Publishing Group
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Rivas, M. A., D. Graham, P. Sulem, C. Stevens, A. N. Desch, P. Goyette, D. Gudbjartsson, et al. 2016. “A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis.” Nature Communications 7 (1): 12342. doi:10.1038/ncomms12342. http://dx.doi.org/10.1038/ncomms12342.

Abstract

Protein-truncating variants protective against human disease provide in vivo validation of therapeutic targets. Here we used targeted sequencing to conduct a search for protein-truncating variants conferring protection against inflammatory bowel disease exploiting knowledge of common variants associated with the same disease. Through replication genotyping and imputation we found that a predicted protein-truncating variant (rs36095412, p.R179X, genotyped in 11,148 ulcerative colitis patients and 295,446 controls, MAF=up to 0.78%) in RNF186, a single-exon ring finger E3 ligase with strong colonic expression, protects against ulcerative colitis (overall P=6.89 × 10−7, odds ratio=0.30). We further demonstrate that the truncated protein exhibits reduced expression and altered subcellular localization, suggesting the protective mechanism may reside in the loss of an interaction or function via mislocalization and/or loss of an essential transmembrane domain.

Description

Research Data

Keywords

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories